Abstract
Although international consensus exists that dose intensification improves outcomes for patients with radiographically localised Ewing sarcoma, treatment strategies to achieve this intensification, and how to translate this improvement to patients with metastatic disease, has remained controversial and enigmatic.1–4 An intercontinental divide for the upfront treatment of Ewing sarcoma has persisted: patients in Europe are most often offered induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE), and consolidation with vincristine, actinomycin D, and ifosfamide or cyclophosphamide (VAI or VAC), or busulfan and melphalan (BuMel), whereas in the USA the standard of care consists of interval-compressed cycles of cyclophosphamide, doxorubicin, and vincristine (VDC) plus ifosfamide and etoposide (IE).
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
